Therapy Advancements and Biomarker Identifications Leading to Improved Ability to Predict and Enhance Responses To Immunotherapeutic Agents In Non–Small Cell Lung Cancer (NSCLC)

Therapy Advancements and Biomarker Identifications Leading to Improved Ability to Predict and Enhance Responses To Immunotherapeutic Agents In Non–Small Cell Lung Cancer (NSCLC)

Targeted therapy advancements and the identification of emerging biomarkers of response to treatment have led to an improved ability to predict and enhance responses to immunotherapeutic agents in non–small cell lung cancer (NSCLC). Available agents that have...

Pin It on Pinterest